Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study to Evaluate [18F]ACI-19626 As a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients with Suspected TDP-43 Proteinopathies Compared with Healthy Controls

Next Previous
Trial Profile

Phase 1 Study to Evaluate [18F]ACI-19626 As a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients with Suspected TDP-43 Proteinopathies Compared with Healthy Controls

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 15 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACI 19626 (Primary)
  • Indications Frontotemporal dementia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors AC Immune

Most Recent Events

  • 22 May 2026 According to an AC Immune media release, Part 1 investigating ACI-19626 in healthy volunteers and patients with genetic FTD is completed. The Part 2 expansion has started and may include up to 30 patients with FTD, ALS or LATE.
  • 22 May 2026 According to an AC Immune media release, the company announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography (PET) tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis (ALS) at the 2026 TDP43 Summit in Madison, Wisconsin.
  • 22 May 2026 Results presented in an AC Immune Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top